Cedrus LLC Makes New Investment in Intuitive Surgical, Inc. (NASDAQ:ISRG)

Cedrus LLC purchased a new stake in Intuitive Surgical, Inc. (NASDAQ:ISRG) during the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 424 shares of the medical equipment provider’s stock, valued at approximately $208,000.

Other institutional investors and hedge funds also recently modified their holdings of the company. Creekmur Asset Management LLC lifted its stake in Intuitive Surgical by 200.0% in the 1st quarter. Creekmur Asset Management LLC now owns 63 shares of the medical equipment provider’s stock valued at $25,000 after acquiring an additional 42 shares in the last quarter. Ridgewood Investments LLC acquired a new stake in shares of Intuitive Surgical in the second quarter valued at approximately $26,000. Delos Wealth Advisors LLC lifted its position in shares of Intuitive Surgical by 380.0% in the first quarter. Delos Wealth Advisors LLC now owns 72 shares of the medical equipment provider’s stock worth $29,000 after purchasing an additional 57 shares in the last quarter. LRI Investments LLC acquired a new position in Intuitive Surgical during the first quarter worth $30,000. Finally, LGT Financial Advisors LLC grew its position in Intuitive Surgical by 415.4% in the second quarter. LGT Financial Advisors LLC now owns 67 shares of the medical equipment provider’s stock valued at $30,000 after purchasing an additional 54 shares in the last quarter. 83.64% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Intuitive Surgical news, Director Amal M. Johnson sold 2,943 shares of Intuitive Surgical stock in a transaction on Thursday, August 1st. The stock was sold at an average price of $443.30, for a total value of $1,304,631.90. Following the completion of the transaction, the director now directly owns 12,275 shares of the company’s stock, valued at $5,441,507.50. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other news, Director Amal M. Johnson sold 2,943 shares of the business’s stock in a transaction that occurred on Thursday, August 1st. The shares were sold at an average price of $443.30, for a total value of $1,304,631.90. Following the completion of the transaction, the director now directly owns 12,275 shares in the company, valued at approximately $5,441,507.50. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Amy L. Ladd sold 450 shares of the company’s stock in a transaction that occurred on Friday, September 13th. The stock was sold at an average price of $490.28, for a total transaction of $220,626.00. Following the sale, the director now directly owns 821 shares of the company’s stock, valued at approximately $402,519.88. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 53,120 shares of company stock valued at $25,528,753 over the last 90 days. 0.90% of the stock is owned by corporate insiders.

Intuitive Surgical Stock Performance

NASDAQ:ISRG opened at $521.15 on Monday. Intuitive Surgical, Inc. has a 52 week low of $254.85 and a 52 week high of $523.34. The firm’s 50-day simple moving average is $483.85 and its 200 day simple moving average is $438.56. The firm has a market cap of $184.85 billion, a price-to-earnings ratio of 94.07, a P/E/G ratio of 5.40 and a beta of 1.39.

Intuitive Surgical (NASDAQ:ISRG) last announced its earnings results on Thursday, July 18th. The medical equipment provider reported $1.78 EPS for the quarter, topping the consensus estimate of $1.54 by $0.24. The company had revenue of $2.01 billion for the quarter, compared to analysts’ expectations of $1.97 billion. Intuitive Surgical had a net margin of 27.65% and a return on equity of 13.04%. The business’s revenue for the quarter was up 14.5% on a year-over-year basis. During the same period last year, the firm earned $1.18 earnings per share. Sell-side analysts anticipate that Intuitive Surgical, Inc. will post 5.22 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on the stock. Raymond James boosted their price target on shares of Intuitive Surgical from $500.00 to $540.00 and gave the stock an “outperform” rating in a research report on Monday, October 14th. Stifel Nicolaus increased their price target on Intuitive Surgical from $475.00 to $525.00 and gave the company a “buy” rating in a research report on Friday. Citigroup boosted their price target on Intuitive Surgical from $512.00 to $560.00 and gave the stock a “buy” rating in a research report on Thursday, August 22nd. Redburn Atlantic raised Intuitive Surgical from a “neutral” rating to a “buy” rating and increased their price objective for the company from $380.00 to $510.00 in a report on Friday, August 2nd. Finally, Royal Bank of Canada raised their target price on shares of Intuitive Surgical from $525.00 to $555.00 and gave the company an “outperform” rating in a research note on Friday. One analyst has rated the stock with a sell rating, five have given a hold rating and fourteen have given a buy rating to the company’s stock. Based on data from MarketBeat, Intuitive Surgical currently has an average rating of “Moderate Buy” and a consensus price target of $513.74.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.